IARTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
INTEGRA LIFESCIENCES HOLDINGS CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 23, 2026
$13.45+0.24 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $1.05B
- P/E (TTM)
- –
- Dividend yield
- –
INTEGRA LIFESCIENCES HOLDINGS CORP revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialty Surgery | $309.27M | $283.14M | – | – | $303.96M | $280.66M | – | – | – | – | – | – | 73.9% | +1.7% |
| Tissue Reconstruction | $109.49M | $108.78M | – | – | $111.65M | $101.99M | – | – | – | – | – | – | 26.1% | -1.9% |
| Specialty Surgery | – | – | $323.31M | $292.58M | $303.96M | $280.66M | $314.66M | $270.78M | $301.76M | $256.43M | $271.62M | $268.21M | – | – |
| Tissue Technologies | – | – | $111.62M | $109.48M | $111.65M | $101.99M | $127.99M | $110.05M | $116.41M | $112.44M | $125.42M | $114.22M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialty Surgery | $88.87M | $83.13M | – | – | -$302.19M | $72.22M | – | – | – | – | – | – | -129.4% |
| Tissue Reconstruction | $18.94M | $20.27M | – | – | -$119.35M | $4.44M | – | – | – | – | – | – | -115.9% |
| Specialty Surgery | – | – | $143.43M | $130.23M | -$263.05M | $110.36M | $135.90M | $100.54M | $164.14M | $103.49M | $118.09M | $105.17M | – |
| Tissue Technologies | – | – | $30.10M | $27.14M | -$105.03M | $16.05M | $42.83M | $28.48M | $37.19M | $30.67M | $41.92M | $31.79M | – |
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $307.10M | $289.38M | $320.37M | $295.85M | $306.31M | $282.22M | $336.03M | $290.19M | $310.23M | $256.23M | $283.11M | $269.84M | 73.3% | +0.3% |
| Asia Pacific | $48.70M | $45.21M | $53.73M | $42.68M | $47.73M | $45.11M | $44.07M | $37.05M | $45.95M | $49.55M | $46.14M | $48.78M | 11.6% | +2.0% |
| Europe | $42.57M | $39.96M | $41.85M | $42.89M | $42.59M | $35.33M | $41.84M | $34.37M | $40.69M | $41.60M | $45.18M | $41.52M | 10.2% | -0.1% |
| Rest of World | $20.39M | $17.36M | $18.96M | $20.64M | $18.97M | $20.01M | $20.71M | $19.22M | $21.31M | $21.50M | – | – | 4.9% | +7.5% |
| Rest of World | – | – | – | – | – | – | – | $19.22M | $21.31M | $21.50M | $22.61M | $22.28M | – | – |
From the segment and revenue-disaggregation notes of Integra Lifesciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.